Next Article in Journal
Risk Allele Frequency Analysis of Single-Nucleotide Polymorphisms for Vitamin D Concentrations in Different Ethnic Group
Next Article in Special Issue
The Role of NEDD4 E3 Ubiquitin–Protein Ligases in Parkinson’s Disease
Previous Article in Journal
Antibacterial Peptides Resistance in Staphylococcus aureus: Various Mechanisms and the Association with Pathogenicity
Previous Article in Special Issue
Roles for α-Synuclein in Gene Expression
 
 
Review

Genetically Targeted Clinical Trials in Parkinson’s Disease: Learning from the Successes Made in Oncology

1
Herantis Pharma Plc, Bertel Jungin Aukio 1, 02600 Espoo, Finland
2
Department Health Sciences, Umeå University, 907 36 Umeå, Sweden
3
Department of Neurology, Karolinska University Hospital, 171 77 Stockholm, Sweden
4
Department of Neurology, Lund University Hospital, 221 00 Lund, Sweden
*
Author to whom correspondence should be addressed.
Academic Editor: Allison D. Ebert
Genes 2021, 12(10), 1529; https://doi.org/10.3390/genes12101529
Received: 31 May 2021 / Revised: 17 September 2021 / Accepted: 24 September 2021 / Published: 28 September 2021
(This article belongs to the Special Issue Preclinical and Clinical Genetics in Parkinson’s Disease)
Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 genes associated with Parkinson’s disease (PD), most of which are highly penetrant and often cause early onset or atypical signs and symptoms, and an increasing understanding of the associated pathophysiology culminating in dopaminergic neurodegeneration, applying the technologies and designs into the field of neurodegeneration seems a logical step. This review describes some of the methods used in oncology clinical trials and some attempts in Parkinson’s disease and the potential of further implementing genetics, biomarkers and smart clinical trial designs in this disease area. View Full-Text
Keywords: Parkinson’s disease; neurodegenerative disorders; genetic targets; clinical trials; oncology; precision medicine Parkinson’s disease; neurodegenerative disorders; genetic targets; clinical trials; oncology; precision medicine
Show Figures

Figure 1

MDPI and ACS Style

Sjögren, M.; Huttunen, H.J.; Svenningsson, P.; Widner, H. Genetically Targeted Clinical Trials in Parkinson’s Disease: Learning from the Successes Made in Oncology. Genes 2021, 12, 1529. https://doi.org/10.3390/genes12101529

AMA Style

Sjögren M, Huttunen HJ, Svenningsson P, Widner H. Genetically Targeted Clinical Trials in Parkinson’s Disease: Learning from the Successes Made in Oncology. Genes. 2021; 12(10):1529. https://doi.org/10.3390/genes12101529

Chicago/Turabian Style

Sjögren, Magnus, Henri J. Huttunen, Per Svenningsson, and Håkan Widner. 2021. "Genetically Targeted Clinical Trials in Parkinson’s Disease: Learning from the Successes Made in Oncology" Genes 12, no. 10: 1529. https://doi.org/10.3390/genes12101529

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop